Could blocking a hormone be the key to menopausal bone health?
NCT ID NCT07254429
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether blocking a hormone called LH can improve bone health in menopausal women. 192 women with moderate-to-severe hot flashes will receive either a GnRH analog, estrogen, testosterone, or a placebo for 8 weeks. The goal is to find a safer alternative to estrogen therapy for preventing bone loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Triptorelin (GnRH analog), Estradiol, Testosterone
- What this could lead to
- If successful, this could point toward a new hormone-blocking treatment for menopausal bone loss that avoids the risks of estrogen therapy.
- What could go wrong
- This is a small, early-phase trial with only 192 participants over 8 weeks. The results may not apply to all women, and the GnRH analog may cause side effects like hot flashes or mood changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE MARKERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Division of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital Herlev.
RECRUITINGHerlev, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.